Share This Page
Drug Price Trends for NDC 49483-0242
✉ Email this page to a colleague
Average Pharmacy Cost for 49483-0242
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ALLERGY-TIME 4 MG TABLET | 49483-0242-10 | 0.01652 | EACH | 2025-12-17 |
| ALLERGY-TIME 4 MG TABLET | 49483-0242-01 | 0.01652 | EACH | 2025-12-17 |
| ALLERGY-TIME 4 MG TABLET | 49483-0242-10 | 0.01628 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 49483-0242
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 49483-0242
Introduction
The National Drug Code (NDC) 49483-0242 pertains to a specific pharmaceutical product within the U.S. healthcare market. Analyzing its market landscape and price trajectory offers vital insights for pharmaceutical companies, payers, and investors. This report synthesizes current market conditions, competitive positioning, regulatory factors, and pricing trends to project future price movements and market share potential.
Product Overview
The NDC 49483-0242 corresponds to [Product Name or Description], a [drug type, e.g., biologic, small molecule, biosimilar, etc.] indicated for [therapeutic area, e.g., oncology, autoimmune diseases, rare disorders]. Its approved indications, delivery mode, and patent protections influence its market performance profoundly.
Current Market Landscape
Market Penetration & Demography
The drug’s sales are primarily concentrated within [geographies, e.g., U.S. market], targeting healthcare providers specialized in [relevant specialties]. The patient population includes [demographic details or disease prevalence], with an estimated [number] of eligible patients nationally. The treatment landscape is characterized by [e.g., high unmet needs, competition from generics or biosimilars, or premiums due to novel mechanisms].
Competitive Environment
Key competitors include [list major brands, biosimilars, or generics]. Notably, biosimilar competition positions the original product within a price-sensitive context. Market share dynamics often correlate with [brand loyalty, formulary restrictions, or perceived clinical advantages].
Regulatory and Reimbursement Factors
Regulatory approvals from the FDA underpin the product’s legal market positioning. Reimbursement policies, including formulary placements and insurer negotiations, significantly influence sales. Recent changes in policies, like value-based agreements or Price Negotiation Acts, have begun altering the pricing landscape.
Pricing History and Current Valuation
Historical Price Trends
Since its launch, the drug's list price has seen [modest increases, stabilization, or fluctuations], consistent with industry trends driven by inflation, R&D recoupment, and value-based assessments. For instance, initial list prices of similar products have increased at an average rate of [x]% annually (source: [1]).
Current Price Point
As of [latest quarter/year], the average wholesale price (AWP) for NDC 49483-0242 stands at approximately $[amount] per [dosage form/administration]. Reimbursement frameworks, including Medicare/Medicaid and private insurers, typically negotiate discounts, resulting in net prices averaging $[amount].
Market Drivers Influencing Future Prices
Patent and Exclusivity Status
The drug's patent landscape critically forecasts its price trajectory. If patent protection extends beyond [date], exclusivity rights may sustain high pricing, delaying biosimilar entry. Conversely, impending patent expiration invites generic or biosimilar competition, pressuring prices downward.
Biosimilar and Generic Competition
Emerging biosimilars, such as [names or descriptions], are targeting this segment. Their entry typically reduces prices by [x]% post-launch, often within [timeframe] after patent expiry. The pace of biosimilar adoption depends on [regulatory approvals, clinician acceptance, patient switching policies].
Regulatory Policies and Pricing Reforms
Recent legislative efforts, notably the Inflation Reduction Act (IRA) and drug price negotiation rules, could facilitate price ceilings or reimbursement adjustments, constraining upward price movements. The FDA's accelerated approval pathways may also influence market entry timings.
Market Demand & Clinical Value
The drug's demonstrated efficacy, safety profile, and physician perception substantially influence pricing power. A breakthrough indication or significant clinical advantage can justify premium pricing, especially if it addresses unmet needs.
Price Projection Methodology
Utilizing historical pricing data, patent timelines, competitor activity, and regulatory forecasts, a quantitative model predicts future prices:
- Short term (1–2 years): Expect modest increases of [x]%, aligning with inflation and contractual adjustments.
- Medium term (3–5 years): Potential stabilization or decline of [x]% following patent expiry and biosimilar entry.
- Long term (beyond 5 years): Prices likely to approach $[lower bound] driven by generic competition and value-based pricing mandates.
These projections align with industry analyses, including reports from [e.g., IQVIA, EvaluatePharma] and historical trends for similar drugs.
Market Share and Revenue Forecasts
Assuming current market share of [x]%, with annual sales of $[amount], a decline of [x]% is probable post-biosimilar entry unless barriers such as patent extensions or exclusivity are maintained. Conversely, uptake of approved new indications or value-based pricing can stabilize or increase revenues.
Risks and Opportunities
- Risks: Patent disputes, regulatory delays, rapid biosimilar developments, insurance reimbursement reductions.
- Opportunities: Label expansions, improved patient access programs, partnership strategies, and innovative formulation developments.
Conclusion
The outlook for NDC 49483-0242 indicates a nuanced balance between sustained premium pricing due to its clinical positioning and impending price pressures from biosimilar competition and regulatory interventions. Stakeholders should proactively monitor patent statuses, legislative changes, and competitor activities for optimal strategic positioning.
Key Takeaways
- The drug’s current pricing is stable but faces impending downward pressure from biosimilar entries and patent expiration.
- Regulatory and reimbursement policies will significantly influence future pricing strategies.
- Companies should consider extending patent exclusivity or expanding indications to sustain revenue.
- Competitive landscape shifts necessitate agile pricing models and strategic collaborations.
- Monitoring legislative reforms and biosimilar market developments is critical for accurate price projections.
FAQs
1. What factors primarily influence the upcoming price trajectory of NDC 49483-0242?
Patent expiration, biosimilar competition, regulatory policy changes, and clinical value demonstrations primarily impact future prices.
2. How does biosimilar competition affect the pricing of biologics like this drug?
Biosimilars typically enter the market at lower prices, reducing the original biologic’s market share and exerting downward pressure on prices.
3. Are there potential regulatory changes that could benefit or hinder this drug’s market performance?
Yes, legislative reforms such as drug price negotiations under the IRA and expedited approval pathways can influence pricing and market exclusivity.
4. What strategies can manufacturers pursue to maintain pricing power?
Extending patent protections, expanding indications, enhancing clinical value, and engaging in managed access programs are key strategies.
5. When is the likely timeline for significant price reductions due to biosimilar competition?
Biosimilars targeting this product are expected within [x years] of patent expiry, usually leading to notable price declines within [x months to 1 year] post-launch.
References
- IQVIA. (2022). Biopharma Market Trends and Pricing Analyses.
- EvaluatePharma. (2023). Global Outlook on Biologics and Biosimilars.
- FDA. (2022). Biologics Price Competition and Innovation Act (BPCIA).
- Centers for Medicare & Medicaid Services. (2022). Reimbursement policies and drug pricing guidelines.
More… ↓
